Literature DB >> 9819779

Estrogen for women at varying risk of coronary disease.

F Grodstein1, M J Stampfer.   

Abstract

Many epidemiological studies show that women who use estrogen therapy after menopause have significantly lower rates of heart disease than postmenopausal women who do not take estrogen. However, few studies have assessed the impact of estrogen use among women with a distinctly higher cardiovascular risk. Seven studies of estrogen therapy in women with established coronary heart disease (such as, coronary stenosis and prior myocardial infarction) are briefly reviewed. These studies all find fewer recurrent cardiovascular events and an improved survival in the estrogen group when compared to the non-estrogen group. Analysis of the effect of estrogen within different risk factor categories in the 16-year follow up of the Nurses' Health Study confirms that although relevant risk estimates are highly similar, the magnitude of the protective effect of estrogen is more pronounced among women with high baseline risk of disease.

Entities:  

Mesh:

Year:  1998        PMID: 9819779     DOI: 10.1016/s0378-5122(98)00055-3

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  13 in total

Review 1.  What is the cardioprotective role of hormone replacement therapy?

Authors:  Howard N Hodis; Wendy J Mack; Roger Lobo
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

Review 2.  A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent.

Authors:  Howard N Hodis; Wendy J Mack
Journal:  Brain Res       Date:  2010-10-25       Impact factor: 3.252

3.  The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective.

Authors:  H N Hodis; P Collins; W J Mack; L Lind Schierbeck
Journal:  Climacteric       Date:  2012-06       Impact factor: 3.005

Review 4.  Postmenopausal hormone therapy: risks and benefits.

Authors:  Serge Rozenberg; Jean Vandromme; Caroline Antoine
Journal:  Nat Rev Endocrinol       Date:  2013-02-19       Impact factor: 43.330

5.  Methods and baseline cardiovascular data from the Early versus Late Intervention Trial with Estradiol testing the menopausal hormone timing hypothesis.

Authors:  Howard N Hodis; Wendy J Mack; Donna Shoupe; Stanley P Azen; Frank Z Stanczyk; Juliana Hwang-Levine; Matthew J Budoff; Victor W Henderson
Journal:  Menopause       Date:  2015-04       Impact factor: 2.953

Review 6.  Postmenopausal hormone replacement therapy as antiatherosclerotic therapy.

Authors:  Howard N Hodis; Wendy J Mack; Roger Lobo
Journal:  Curr Atheroscler Rep       Date:  2002-01       Impact factor: 5.113

Review 7.  Postmenopausal hormone therapy and cardiovascular disease in perspective.

Authors:  Howard N Hodis; Wendy J Mack
Journal:  Clin Obstet Gynecol       Date:  2008-09       Impact factor: 2.190

Review 8.  Postmenopausal hormone therapy: impact on menopause-related symptoms, chronic disease and quality of life.

Authors:  Marius Jan van der Mooren; Peter Kenemans
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Identification of a CYP19 Gene Single-Nucleotide Polymorphism Associated with a Reduced Risk of Coronary Heart Disease.

Authors:  Bei Wang; Zhen-Yan Fu; Yi-Tong Ma; Ding Huang; Fen Liu; Chun-Lan Dong; Ting Wang; Ya-Jie Meng
Journal:  Genet Test Mol Biomarkers       Date:  2015-11-12

10.  Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.

Authors:  H Michael; P L Härkönen; L Kangas; H K Väänänen; T A Hentunen
Journal:  Br J Pharmacol       Date:  2007-04-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.